

1st Quarter 2021 Results

1st Quarter 2021 Sales

\$22.3B	Worldwide Increased ▲		Excluding acquisitions/ divestitures on an operational basis	Worldwide Increased ▲
	7.9%			6.0%*

Diluted Earnings Per Share

Adjusted Diluted Earnings Per Share*

\$2.32	Increased ▲		\$2.59	Increased ▲
	6.9%			12.6%



Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

“Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices. The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere.”

**\$3.5
Billion**

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales decreased (2.3)% or (3.3)% operationally¹. Primary offsets to decline:



LISTERINE

Johnson's

Aveeno




Pepcid



**\$12.2
Billion**

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 9.6% or 7.1% operationally¹. Primary operational drivers:



Stelara
(ustekinumab)

DARZALEX
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

imbruvica
(ibrutinib)
560, 420, 280, 140 mg tablets | 140, 70 mg capsules

Tremfya
(guselkumab)

Erleada
(apalutamide) 60 mg tablets

Upravi
selexipag
tablets | 200-1600 mcg

INVEGA SUSTENNA
paliperidone palmitate
extended-release
orally disintegrating tablets

Opsumit
macitentan

**\$6.6
Billion**

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales increased 10.9% or 8.0% operationally¹. Primary operational drivers:



Electrophysiology

Endocutters

Biosurgery

Energy

Wound Closure

Surgical Vision

Trauma

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on April 20, 2021, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on April 20, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.